WHO Introduces Faster, More Accessible TB Testing Strategies While CDC Maintains a Targeted, Risk-Based Approach in the United States.

The World Health Organization (WHO) has unveiled a suite of groundbreaking recommendations aimed at revolutionizing tuberculosis (TB) diagnostics, emphasizing speed, accessibility, and cost-efficiency. These new guidelines, detailed in a recent news release and expected to be fully integrated into WHO’s updated Module 3: Diagnosis guidelines later this year, introduce near point-of-care molecular testing, innovative alternative sample collection methods, and pragmatic pooled testing strategies. This global pivot seeks to bridge persistent diagnostic gaps and accelerate the path to treatment, particularly in resource-limited and high-burden settings.

Simultaneously, the Centers for Disease Control and Prevention (CDC) in the United States continues to uphold a distinct, targeted, and risk-based approach to TB testing. This divergence in strategy underscores the varying epidemiological landscapes and public health priorities between global efforts to combat a widespread disease and national strategies within a lower-incidence environment.

The Global Imperative: Bridging Diagnostic Gaps in TB Control

Tuberculosis remains one of the world’s deadliest infectious diseases, claiming millions of lives annually. In 2022 alone, an estimated 10.6 million people fell ill with TB worldwide, and 1.3 million died from it, according to WHO data. The disease disproportionately affects vulnerable populations in low- and middle-income countries, where access to advanced diagnostics and timely treatment is often severely limited. For decades, TB diagnosis has relied heavily on sputum smear microscopy, a method known for its low sensitivity, especially in children and people with HIV, and its inability to detect drug resistance. Culture-based methods, while more sensitive, are time-consuming, often taking weeks to yield results, leading to significant treatment delays and continued transmission.

Rapid molecular tests, such as Xpert MTB/RIF, represented a significant leap forward when introduced over a decade ago, offering faster and more accurate diagnosis with simultaneous detection of rifampicin resistance. However, these systems often require centralized laboratory infrastructure, consistent power supply, and trained personnel, limiting their reach in many remote and underserved areas. This reliance on centralized facilities means many patients still face long journeys, significant costs, and extended waiting periods for results, exacerbating the global diagnostic gap. The WHO’s new recommendations directly address these systemic challenges.

WHO’s Transformative Recommendations: A Closer Look

The core of WHO’s updated guidance centers on three pivotal innovations designed to decentralize and streamline TB diagnostics:

Near Point-of-Care Nucleic Acid Amplification Tests (NPOC-NAATs): For the first time, WHO is endorsing a new class of NPOC-NAATs. Unlike their predecessors, these systems are engineered for deployment in decentralized settings, such as primary care clinics, community health centers, and even mobile units. The key advantage of NPOC-NAATs lies in their ability to deliver rapid, accurate molecular results much closer to the patient, often within hours. This significantly reduces turnaround times, which are critical for initiating prompt treatment, minimizing disease progression, and curbing transmission. The lower operational cost per test compared to traditional laboratory-based molecular platforms further enhances their suitability for resource-constrained environments, potentially making high-quality molecular diagnostics accessible to a much broader population. This shift represents a strategic move towards "test-and-treat" models where a diagnosis can be made and treatment commenced during a single patient visit or shortly thereafter.
Alternative Sample Collection Methods – Tongue Swabs: Recognizing the challenges associated with sputum collection, particularly in vulnerable groups, the updated guidance endorses tongue swabs as a viable alternative specimen type for TB detection. Sputum collection can be difficult for children, individuals who are severely ill, or those with non-productive coughs. It can also be stigmatizing and logistically complex in community settings. Tongue swabs offer a non-invasive, easier-to-collect alternative that can be performed by less specialized personnel, potentially expanding screening efforts into community outreach programs and home-based care. While research continues to optimize the sensitivity and specificity of TB detection from tongue swabs, their inclusion in WHO guidelines signifies a commitment to making sample collection more patient-friendly and broadly applicable.
Sputum Pooling Strategies: To enhance efficiency and conserve valuable reagents, especially in resource-constrained laboratories, WHO now recommends sputum pooling. This strategy involves combining multiple sputum samples (e.g., 5-10 samples) into a single batch for initial molecular testing. If the pooled sample tests negative, all individual samples within that pool are presumed negative. If the pool tests positive, then individual samples from that pool are retested to identify the positive case(s). This approach can significantly reduce the number of individual tests required, thereby cutting costs and conserving reagents without compromising diagnostic accuracy in settings with lower TB prevalence or during mass screening campaigns. Sputum pooling allows laboratories to increase throughput, making better use of existing resources and expanding diagnostic capacity.

Dr. Tereza Kasaeva, director of WHO’s Department for HIV, TB, Hepatitis & STIs, underscored the significance of these advancements, stating, “These new WHO recommendations mark a major step forward in making TB testing faster and more accessible. WHO urges countries and partners to work together to roll out these guidelines to close persistent diagnostic gaps and ensure that everyone with TB can be diagnosed early and start life-saving treatment without delay.” This statement, accompanied by a photo of Dr. Kasaeva, highlights the urgency and collaborative spirit behind these global efforts.

The expected operational handbook and implementation toolkit will provide practical guidance for national TB programs and clinical laboratories on adopting these new strategies, including training, workflow integration, and quality assurance.

The US Context: CDC’s Targeted Approach Amidst Rising Cases

In stark contrast to WHO’s global push for expanded, decentralized access, the CDC maintains a more targeted testing strategy for tuberculosis within the United States. This approach focuses primarily on screening individuals identified as being at high risk for TB infection or disease, rather than widespread, universal screening. This strategy is largely informed by the lower overall incidence of TB in the U.S. compared to many other parts of the world and the availability of robust healthcare infrastructure.

However, the CDC has noted a concerning trend: TB case counts and rates in the U.S. have been increasing since 2021. In late 2025, the CDC reported a 7.9% increase in case count and a 6.9% increase in rate in 2024 compared to the previous year. Specifically, 2024 saw 10,388 TB cases in the U.S., corresponding to an incidence rate of 3.1 per 100,000 population. While still relatively low on a global scale, this upward trend necessitates vigilance and strategic allocation of diagnostic resources. Possible factors contributing to this increase include delayed diagnoses during the COVID-19 pandemic, increased migration from high-burden countries, and underlying social determinants of health.

CDC’s Multi-Faceted Diagnostic Framework

The CDC’s guidance outlines a comprehensive framework for TB detection and diagnosis, distinguishing between tests for TB infection and the full diagnostic evaluation for active disease.

Two Types of TB Infection Tests:
The CDC recognizes two primary methods to detect TB infection, though neither distinguishes between latent infection (LTBI) and active disease:

Tuberculin Skin Test (TST): Also known as the Mantoux test, the TST involves injecting a small amount of tuberculin purified protein derivative (PPD) into the forearm. A healthcare worker then measures the induration (hardening) at the injection site 48 to 72 hours later. While historically a cornerstone of TB screening, the TST has limitations, including the need for a follow-up visit, potential for false positives in individuals who have received the Bacillus Calmette-Guérin (BCG) vaccine, and variability in interpretation.
Interferon-Gamma Release Assays (IGRAs): These blood tests measure the immune response to TB-specific antigens. Examples include QuantiFERON®-TB Gold Plus and T-SPOT.TB®. IGRAs offer several advantages over TSTs: they require only a single patient visit, results are available within 24-48 hours, and they are less affected by prior BCG vaccination, leading to fewer false-positive results. The CDC strongly prefers IGRAs for individuals who have received the BCG vaccine due to their higher specificity.

Five Components of a Full Diagnostic Evaluation:
If a patient tests positive for TB infection or presents with symptoms suggestive of active TB (such as chronic cough, night sweats, fever, unexplained weight loss, or fatigue), the CDC recommends a comprehensive evaluation comprising:

Medical History: A thorough review of symptoms, past medical conditions, exposure history (e.g., contact with someone with active TB), and risk factors for TB progression (e.g., HIV infection, immunosuppression, substance abuse, diabetes).
Physical Examination: A clinical assessment to identify signs consistent with active TB, particularly lung involvement, although extrapulmonary TB can affect other organs.
Chest Radiograph (X-ray): An imaging study crucial for identifying lung abnormalities characteristic of TB disease, such as infiltrates, cavities, or lymphadenopathy. A normal chest X-ray generally rules out pulmonary TB disease, but cannot rule out LTBI or extrapulmonary TB.
Microbiological Studies: This is paramount for confirming active TB and identifying the specific Mycobacterium tuberculosis bacterium. It typically involves:
- Sputum smear microscopy: Rapid detection of acid-fast bacilli (AFB), providing an initial indication of infectivity.
- Nucleic Acid Amplification Tests (NAATs): Highly sensitive and specific molecular tests that rapidly detect TB DNA/RNA from respiratory or other samples, often with simultaneous detection of drug resistance mutations.
- Culture: The gold standard for confirming TB diagnosis and for drug susceptibility testing, as it allows for the growth and identification of the organism. Culture results, however, can take weeks.
Drug Susceptibility Testing (DST): Once M. tuberculosis is confirmed, DST is critical to determine which anti-TB drugs will be effective. This helps guide appropriate treatment regimens, prevent the development of drug-resistant TB, and ensure optimal patient outcomes. DST should be performed on the initial isolate from all patients with active TB.

Updated Guidance for Healthcare Personnel (HCP):
Recent CDC guidance, developed in collaboration with the National Tuberculosis Controllers Association, reflects an evolving understanding of occupational risk and aims to optimize screening practices for healthcare workers:

Baseline Screening: All new HCP should receive baseline TB screening upon hiring.
Risk Assessment: An individual risk assessment should be conducted for all HCP, including evaluating their potential for TB exposure in the workplace and their personal risk factors.
Symptom-Based Screening: Routine annual TB testing for HCP is no longer universally recommended. Instead, symptom-based screening is emphasized for all HCP, regardless of their baseline test results. HCP should be educated to recognize and report TB symptoms promptly.
Targeted Follow-up: Only HCP with ongoing risk of exposure (e.g., those working in settings with known TB transmission) or those with symptoms suggestive of TB should undergo additional testing.

For 2026, the CDC further stresses important nuances for clinicians and laboratories interpreting TB test results. For individuals considered low risk for TB, a positive result should ideally be confirmed with a second test—preferably using a different method (e.g., an IGRA after a TST, or vice versa)—before initiating treatment. This strategy helps to minimize false positives, avoid unnecessary therapy, and ensure diagnostic accuracy in a low-prevalence setting.

Implications for Clinical Laboratories: Navigating Divergent Strategies

The parallel, yet distinct, strategies articulated by the WHO and CDC present both opportunities and complexities for clinical laboratories worldwide. The WHO’s recommendations signal a global trajectory towards decentralized, rapid, and cost-efficient diagnostics, particularly for high-burden regions. This necessitates the adoption of new NPOC-NAAT platforms, validation of alternative specimen types like tongue swabs, and the implementation of sophisticated pooling algorithms to maximize resource utilization. Laboratories in these settings will require significant investment in training, infrastructure upgrades, and robust quality assurance programs to ensure the reliability of these new approaches.

Conversely, clinical laboratories in countries like the United States must continue to refine their targeted, risk-based approach. This involves mastering the nuanced interpretation of IGRAs, especially for BCG-vaccinated individuals, maintaining high standards for comprehensive diagnostic panels (including advanced molecular tests for active disease and rapid drug susceptibility testing), and contributing to robust surveillance systems. The recent uptick in US TB cases underscores the ongoing need for vigilance and efficient, accurate diagnostics even in a lower-incidence environment.

The evolving landscape of TB diagnostics signifies a dynamic period for public health. While global initiatives driven by the WHO aim to democratize access to rapid testing and accelerate TB elimination, national strategies, as exemplified by the CDC, prioritize targeted interventions tailored to specific epidemiological contexts. Clinical laboratories, at the forefront of this diagnostic evolution, will play a critical role in implementing these diverse strategies, validating new technologies, and ensuring that every patient, regardless of their location, receives an accurate and timely diagnosis of tuberculosis. The ultimate goal remains universal: to end TB as a global public health threat.